Eisai Preps for Alzheimer’s Drug Launch

With the first patients receiving Leqembi last week, the new Alzheimer’s drug’s manufacturer Eisei is plotting out the drug’s rollout with last year’s Aduhelm controversy in mind. As such, the company, which received approval for the drug this January, is taking things slow and working carefully with payers to secure reimbursement ahead of a potential full approval in the near future.

According to Fraiser Kansteiner, “In Leqembi’s case, meanwhile, Eisai is prioritizing access by “accelerating” its efforts with payers, Cheung said. That includes working with CMS to “establish broad and simple Medicare access to Leqembi. Eisai has also been working on coverage through Veterans Affairs, having had “several productive engagements” that could lead to wider Leqembi access even before potential receipt of a full, traditional approval from the FDA.”

To read more, click here.

(Source: Fierce Biotech, February 6^th, 2023)